A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

Sukhmani K. Padda, Karen L. Reckamp, Marianna Koczywas, Joel W. Neal, Jun Kawashima, Shengchun Kong, Daniel B. Huang, Mark Kowalski, Heather A. Wakelee

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science